Arcellx Inc (ACLX)

$114.50 +0.17 (0.15%)
Market Cap 6.69B
Revenue (ttm) 22.29M
Net Income (ttm) -228.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,027.05%
Debt to Equity Ratio 0.00
Volume 1,420,200
Avg Vol 2,309,490
Day's Range N/A - N/A
Shares Out 58.48M
Stochastic %K 75%
Beta 0.23
Analysts Hold
Price Target $112.85

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 327 0630
Address:
800 Bridge Parkway, Redwood City, United States
Innovatenow
Innovatenow Mar. 7 at 5:11 AM
$ACLX https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-is-investigating-the-mergeraclx-vre-ehab-and-ceco-302704159.html
0 · Reply
Mergerbrief
Mergerbrief Mar. 6 at 12:38 PM
$ACLX / $GILD – Tender Offer File By date
0 · Reply
SBroomy
SBroomy Mar. 5 at 6:36 PM
$ACLX $SPY Arcellx have hold up very well since it's gains.
0 · Reply
Achandler787
Achandler787 Mar. 5 at 3:56 AM
$ACLX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 6:59 PM
$ACLX RSI: 85.61, MACD: 11.9080 Vol: 21.44, MA20: 81.95, MA50: 72.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 27 at 2:20 AM
$ACLX congrats longs! $GILD should buy $ALT or $IMRX next 🚀
0 · Reply
IN0V8
IN0V8 Feb. 25 at 6:46 PM
$ACLX 2/24 Citigroup cuts to neutral from buy Citigroup raises target price to $115 from from $110 Leerink Partners cuts to market perform rating Leerink Partners raises target price to $115 from $109 Stifel cuts to hold from buy; cuts target price to $115 from $127 Truist Securities cuts to hold from buy; cuts PT to $120 from $134 UBS cuts to neutral from buy UBS raises target price to $115 from $100 Wells Fargo cuts to equal weight from overweight Wells Fargo raises target price to $115 from $100
0 · Reply
Parobull
Parobull Feb. 25 at 4:41 PM
$HCWC is wildly undervalued. 30M in profits, cash flow positive, heavy shorts, and almost no borrow left. That’s squeeze fuel. Gap sitting in the .50s once it flips, this could move fast. $ATER $ACLX $SGN $ALUR
1 · Reply
6GodEnergy
6GodEnergy Feb. 24 at 11:23 PM
/@SqueezeSharkie is on another level, clearly ahead of most traders here. If you’re serious about leveling up, you should already be following him. It costs nothing, takes seconds, and the results speak for themselves. >>> $MLEC $ACLX $MENS $EZRA
1 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 7:17 PM
$GILD to acquire $ACLX for $115 per share in cash plus a $5 CVR, totaling $7.8B — strengthening its position in cell therapy 🚀 Gilead's strategic acquisition aims to streamline control over anito-cel therapy, enhancing its cell therapy position via Kite Pharma. ACLX shares soared 77.43% on the news. Discover the full implications here 👉 https://www.zacks.com/stock/news/2874572/gild-to-acquire-aclx-for-78b-gain-full-control-of-anito-cel?cid=sm-stocktwits-2-2874572-body-34988&ADID=SYND_STOCKTWITS_TWEET_2_2874572_BODY_34988
0 · Reply
Latest News on ACLX
Top 2 Health Care Stocks That May Crash This Quarter

Mar 4, 2026, 8:55 AM EST - 5 days ago

Top 2 Health Care Stocks That May Crash This Quarter

ANIK

Baron Health Care Fund Q4 2025 Recent Activity

Mar 3, 2026, 10:36 AM EST - 6 days ago

Baron Health Care Fund Q4 2025 Recent Activity

ARQT BSX ELAN MASI RGEN SYK TMO

Baron Health Care Fund Q4 2025 Contributors And Detractors

Mar 3, 2026, 10:18 AM EST - 6 days ago

Baron Health Care Fund Q4 2025 Contributors And Detractors

ARGX DOCS EHC INSM LLY RDNT SYK

Here's Why Shares of Arcellx Are Up Almost 80% Today

Feb 23, 2026, 2:25 PM EST - 14 days ago

Here's Why Shares of Arcellx Are Up Almost 80% Today

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

Feb 23, 2026, 8:41 AM EST - 14 days ago

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

GILD

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Feb 23, 2026, 7:52 AM EST - 14 days ago

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

GILD

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Feb 23, 2026, 6:36 AM EST - 14 days ago

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

GILD

Gilead to acquire Arcellx for $7.8 billion

Feb 23, 2026, 6:08 AM EST - 14 days ago

Gilead to acquire Arcellx for $7.8 billion

GILD

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

Feb 23, 2026, 6:01 AM EST - 14 days ago

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

GILD

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

Feb 23, 2026, 6:01 AM EST - 14 days ago

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

GILD

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

Feb 4, 2026, 9:00 AM EST - 4 weeks ago

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Jan 21, 2026, 4:00 PM EST - 6 weeks ago

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Arcellx: Funded Into 2028 With Strong Clinical Data

Dec 17, 2025, 8:20 AM EST - 2 months ago

Arcellx: Funded Into 2028 With Strong Clinical Data

Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 3 months ago

Cancer Study Buoys These Small Biotechs

LEGN TERN

Why Is Arcellx Stock Surging Today?

Dec 8, 2025, 1:23 PM EST - 3 months ago

Why Is Arcellx Stock Surging Today?

Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript

Dec 7, 2025, 6:28 AM EST - 3 months ago

Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Dec 6, 2025, 2:00 PM EST - 3 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

Nov 18, 2025, 4:00 PM EST - 3 months ago

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

Arcellx Provides Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 4 months ago

Arcellx Provides Third Quarter 2025 Financial Results

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:00 AM EST - 4 months ago

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 3:50 PM EDT - 6 months ago

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

Sep 3, 2025, 4:00 PM EDT - 6 months ago

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

Aug 7, 2025, 9:45 PM EDT - 7 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

BSX EW EXAS GH ISRG LLY MASI

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:00 PM EDT - 7 months ago

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Jul 15, 2025, 4:51 PM EDT - 8 months ago

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 21, 2025, 4:00 PM EDT - 10 months ago

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:00 PM EDT - 10 months ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Apr 29, 2025, 11:45 AM EDT - 11 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ISRG MASI MCK NTRA PEN TMO UNH

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 11 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

BSX DHR GKOS INSM ISRG LLY RDNT

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Mar 18, 2025, 8:44 AM EDT - 1 year ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Arcellx Impressive Safety Data Leaves Doubts

Mar 17, 2025, 11:27 AM EDT - 1 year ago

Arcellx Impressive Safety Data Leaves Doubts

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:00 PM EST - 1 year ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:00 PM EST - 1 year ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Dec 9, 2024, 7:50 AM EST - 1 year ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Dec 8, 2024, 11:00 PM EST - 1 year ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

Jun 26, 2024, 11:19 AM EDT - 1 year ago

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9, 2024, 4:05 PM EDT - 1 year ago

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9, 2024, 4:05 PM EDT - 1 year ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

Arcellx Provides First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results

Arcellx to Participate in Two Upcoming Investor Conferences

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 4:00 PM EDT - 2 years ago

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 20, 2024, 4:00 PM EDT - 2 years ago

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Innovatenow
Innovatenow Mar. 7 at 5:11 AM
$ACLX https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-is-investigating-the-mergeraclx-vre-ehab-and-ceco-302704159.html
0 · Reply
Mergerbrief
Mergerbrief Mar. 6 at 12:38 PM
$ACLX / $GILD – Tender Offer File By date
0 · Reply
SBroomy
SBroomy Mar. 5 at 6:36 PM
$ACLX $SPY Arcellx have hold up very well since it's gains.
0 · Reply
Achandler787
Achandler787 Mar. 5 at 3:56 AM
$ACLX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 6:59 PM
$ACLX RSI: 85.61, MACD: 11.9080 Vol: 21.44, MA20: 81.95, MA50: 72.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 27 at 2:20 AM
$ACLX congrats longs! $GILD should buy $ALT or $IMRX next 🚀
0 · Reply
IN0V8
IN0V8 Feb. 25 at 6:46 PM
$ACLX 2/24 Citigroup cuts to neutral from buy Citigroup raises target price to $115 from from $110 Leerink Partners cuts to market perform rating Leerink Partners raises target price to $115 from $109 Stifel cuts to hold from buy; cuts target price to $115 from $127 Truist Securities cuts to hold from buy; cuts PT to $120 from $134 UBS cuts to neutral from buy UBS raises target price to $115 from $100 Wells Fargo cuts to equal weight from overweight Wells Fargo raises target price to $115 from $100
0 · Reply
Parobull
Parobull Feb. 25 at 4:41 PM
$HCWC is wildly undervalued. 30M in profits, cash flow positive, heavy shorts, and almost no borrow left. That’s squeeze fuel. Gap sitting in the .50s once it flips, this could move fast. $ATER $ACLX $SGN $ALUR
1 · Reply
6GodEnergy
6GodEnergy Feb. 24 at 11:23 PM
/@SqueezeSharkie is on another level, clearly ahead of most traders here. If you’re serious about leveling up, you should already be following him. It costs nothing, takes seconds, and the results speak for themselves. >>> $MLEC $ACLX $MENS $EZRA
1 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 7:17 PM
$GILD to acquire $ACLX for $115 per share in cash plus a $5 CVR, totaling $7.8B — strengthening its position in cell therapy 🚀 Gilead's strategic acquisition aims to streamline control over anito-cel therapy, enhancing its cell therapy position via Kite Pharma. ACLX shares soared 77.43% on the news. Discover the full implications here 👉 https://www.zacks.com/stock/news/2874572/gild-to-acquire-aclx-for-78b-gain-full-control-of-anito-cel?cid=sm-stocktwits-2-2874572-body-34988&ADID=SYND_STOCKTWITS_TWEET_2_2874572_BODY_34988
0 · Reply
IN0V8
IN0V8 Feb. 24 at 4:06 PM
$ACLX 2/23 Baird raises target price to $115 from $106 Piper Sandler cuts to neutral from overweight
0 · Reply
erevnon
erevnon Feb. 24 at 2:23 PM
Citigroup downgrades Arcellx $ACLX from Buy to Neutral and raises the price target from $110 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Feb. 24 at 2:10 PM
Stifel downgrades Arcellx $ACLX from Buy to Hold and lowers the price target from $127 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Joby099
Joby099 Feb. 24 at 10:41 AM
$VNDA $ACLX $GETY $EHAB
0 · Reply
Sarandon
Sarandon Feb. 24 at 8:50 AM
$SABR Jul 2025 = $3.52 Nov 2025 = $2.27 Jan 9 = $1.52 Feb 18 = $1.32 (max day) Feb 19 = $1.07 Feb 20 = $0.97 Feb 23 = $0.90 It's bound to rebound strongly at any moment. 🚀💯 Yesterday it doubled its usual volume... 👀 Other stocks to watch today: $VIR $GNPX $ACLX $GOSS
0 · Reply
RunnerSignals
RunnerSignals Feb. 24 at 4:39 AM
Late night market recap $NVO $ACLX $VRE $IBM $SNOW all saw big swings today from trial news to acquisitions and AI fears. see what is driving the action https://stocksrunner.com/news/2026-02-23-late-night-market-recap
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 24 at 4:25 AM
$ACLX Massive volume spike on Feb 23 with 32.9M shares traded, way above the 859,408 average volume. Price surged from $64.11 to $113.75. Smart move to wait for a lower H% before considering an entry.
0 · Reply
Lanuchbox
Lanuchbox Feb. 24 at 1:08 AM
$ACLX Check it out https://youtu.be/RD7gwRIEEJk?si=o63xc_6iI9XHBhdX
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 24 at 12:03 AM
Comparing trending tickers $ACLX vs $VKTX: ACLX has surged 77.43% to $113.75 with a trading volume of 32.9M shares, significantly above its average of 859.4K. In comparison, VKTX saw a more modest increase of 11.05% to $34.46 on a volume of 5.7M, slightly above its average of 4.4M. While both stocks are experiencing heightened activity, ACLX is displaying markedly stronger price momentum in relation to its usual trading volume.
0 · Reply
CASTMONEY
CASTMONEY Feb. 23 at 11:45 PM
$EZRA $ACLX I SMELL MONEY ALL OVER $$$$$
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 23 at 11:38 PM
Comparing trending tickers $V vs $ACLX: V fell to $306.52, a drop of 4.5%, on a trading volume of 11.5 million shares, which is significantly above its average of 6.8 million. In contrast, ACLX surged 77.43% to $113.75 on an enormous volume of 32.9 million shares, dwarfing its usual volume of 859.4K. While V experienced a notable decline with increased trading activity, ACLX's stock price dramatically increased, indicating a much stronger market reaction to its trading volume.
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 11:34 PM
-@SqueezeSharkie on a different level. Focused, intentional, real game shared. If you’re not tuned in, that’s a miss, make sure to follow him!! Thanks for that sick call btw. $ACLX $VIR $VNDA $ASPS <
0 · Reply